NCT07001254View on ClinicalTrials.gov

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions
Aplastic Anemia
Interventions
DRUG

Romiplostim

The investigational drug, Romiplostim, is a thrombopoietin receptor agonist (TPO-RA) that has been granted orphan drug designation by the FDA.

DRUG

Immunosuppressive therapy (IST)

Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)

Trial Locations (1)

52242

University of Iowa Health Care, Iowa City

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

Food and Drug Administration (FDA)

FED

lead

Anjali Sharathkumar

OTHER